Full Press Release Details
Announces Distribution Agreement
for CGuardTM EPS in Switzerland
Aviv, Israel-August 25, 2017 - InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) ("InspireMD" or the "Company"),
a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it
has signed an agreement with 1a medical ag, a leading medical distributor in Switzerland, to distribute CGuard EPS (Embolic
Gago, EVP and Chief Commercial Officer of InspireMD, commented, "We are delighted to partner with 1a medical ag, which brings
long standing relationships with the top key opinion leaders and physicians across all relevant clinical specialites in Switzerland.
The agreement contains guaranteed minimum sales, further illustrating their confidence in CGuard EPS."
Albert Kaiser, CEO of 1a medical ag, noted, "We look forward to launching CGuard in Switzerland, which is in line
with our mission to bring best-in-class technologies to medical practices across Switzerland. Based on the strong supporting clinical
data, we believe CGuard EPS has the potential to rapidly become standard of care in Switzerland due to its distinct safety
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are
quoted on the NYSE American under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted
or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our
existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to
secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger,
multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange
Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation
to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.